Endocrine Abstracts

Abstract unavailable....

The RANK/RANK ligand (RANKL) pathway is key to promote osteoclast formation and activation, and prolong osteoclast survival. Osteoprotegerin (OPG) acts as a decoy receptor for RANKL and prevents its interaction with RANK thereby inhibiting osteoclast formation, function and survival. In turn RANKL inhibitors, and more specifically a human monoclonal antibody against RANKL, Denosumab, have been developed to treat a variety of bone disorders, including osteoporosis and skeletal ...

The pharmacologic armamentarium available to clinicians to reduce fracture risk in women with postmenopausal osteoporosis consists essentially of antiresorptive agent. Recently, peptides from the parathyroid hormone (PTH) family, which under specific modalities of administration act as anabolic agents have become available. The interest generated by these alternatives to antiresorptive treatment resides in their greater potential for restauration of bone mass and possibly also...